Poster Hall Hours

Tuesday, May 10, 2016
3:00 pm - 6:30 pm

Wednesday, May 11, 2016
10:00 am - 6:30 pm

Thursday, May 12, 2016
10:30 am - 2:00 pm

For more information on how Informa manages and shares your personal data please see our  Privacy Policy


Register now

Date & Time:

January 25th  12:00pm – 1:00pm ET     


2023 is shaping up to be an interesting year for Pharma/Biotech companies and their commercial and government pricing strategies and contracts. There are multiple policies and rules being discussed, already proposed, under review, in litigation, and that need to be implemented this year! Join our experts in this kick-off to ‘23, with a live discussion which will review the evolving healthcare policy and GP regulations. Hear their thoughts on how they will affect you and your company. Expect coverage on:

  • Impacts from the Inflation Reduction Act
  • Updates on Territories and Puerto Rico
  • Changes to Federal and State Drug Pricing, Reimbursement and Transparency
  • 340B
  • Next Gen GPO’s including Safe Harbor and AKS
  • Line Extension identification and evaluations
  • Co-Pay Maximizers and PBM Accumulators


The State of National Healthcare Policy and Pricing Webinar 2023


Jeremy Docken, Founder and Chief Strategy Officer, Kalderos (consultant/solution provider) 

Bio: Jeremy has exhaustive expertise in drug compliance trends and policy from nearly a decade as a consultant to life science and pharmaceutical manufacturers. Driven by witnessing longstanding problems in the drug discount space, Jeremy led the founding of Kalderos in 2016. His passion is solving systemic problems of the healthcare system. 

BioKathy Chaurette is Senior Vice President, Healthcare Law & Compliance at Blueprint Medicines. She has almost 20 years of experience advising biopharmaceutical companies on compliantly structuring comprehensive market access strategies, including pricing and contracting considerations, navigating associated federal and state price reporting requirements, and structuring programs facilitating informed, timely and affordable patient access to prescribed medicines.

Katherine Chaurette, Senior Vice President, Healthcare Law and Compliance, Blueprint Medicines 

Brian McCartney, Senior Director, Market Access Policy & Government Reporting, AstraZeneca  

Michael Kurland, Vice President, Revenue Management & Compliance, EVERSANA (consultant/solution provider)

Bio: With more than 2 decades of experience in the pharmaceutical and biotech industries, Michael helps clients navigate the complex public and private payer marketplace. He has a proven reputation for helping manufacturers balance their market share goals and commercial rebate strategies with government pricing impacts and compliance. Throughout his career, Michael has developed, implemented, and managed business strategies and technical solutions for government pricing, market access, rebate and chargeback processing and data analytics. And, in this context, it makes perfect sense that his areas of expertise include government pricing compliance, public payer strategy development, business analysis, project management, process and system reviews, selections and implementations, and cross-functional team management. Previously, Michael served as director at several life science consulting firms, as well as associate director of government regulated systems at Auxilium Pharmaceuticals, Inc. He holds a bachelor of science degree from Penn State University.

Meena Datta, Partner, Sidley Austin LLP

Craig Bleifer, Partner, Akin, Gump Strauss, Hauer & Feld LLP 

Bio: Craig is an experienced health care executive, having served as corporate vice president and general counsel for Novo Nordisk, and senior vice president, general counsel and secretary for Daiichi Sankyo. As a practicing corporate and health care lawyer for almost 30 years, he advises clients on legal, compliance, policy and regulatory matters relating to health care products and businesses along the full spectrum—from discovery through commercialization. Well versed in the processes and the inner workings of the Food & Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), he advises on clinical studies, inspections and recalls, drug safety programs and negotiates product labeling with the FDA. He advises clients on promotional and medical communications under FDA regulations, guidance and enforcement practices, and First Amendment litigation precedent, including print ads, direct-to-consumer television ads, websites and applications.  

Bio: Meena Datta is global co-leader of the Sidley’s Healthcare practice and member of the global Life Sciences team, manages key strategic matters for life sciences and healthcare companies throughout the world. Meena specializes in all areas of health care regulatory law for pharmaceutical and medical device manufacturers, including the government pricing, Anti-Kickback Statute and state pricing transparency laws, the Sunshine Act, health care reform, and HIPAA and data privacy and security. Her particular areas of focus include patient support programs, market access, and government pricing. She routinely works with General Counsels, Compliance Officers, and their departments to develop and implement effective compliance programs. Meena serves as outside counsel to a wide range of healthcare clients, including emerging and established biopharmaceutical, medtech, and big data companies.